Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 10/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293326 | 0.78 | S1PR1 (0.46) | XDHS1PR1RORC | |
| SCHEMBL1293961 | 0.78 | AAK1 (0.38) | S1PR1RORC | |
| SCHEMBL2446998 | 0.76 | S1PR1 (0.42) | XDHS1PR1RORCCYP2D6 | |
| SCHEMBL2409319 | 0.76 | XDH (0.71) | XDHS1PR1CYP2D6 | |
| SCHEMBL1293378 | 0.75 | S1PR1 (0.55) | XDHS1PR1RORC | |
| SCHEMBL2408148 | 0.73 | S1PR1 (0.51) | XDHS1PR1RORCCYP2D6 | |
| SCHEMBL1293185 | 0.73 | S1PR1 (0.51) | XDHS1PR1RORC | |
| SCHEMBL2409418 | 0.72 | S1PR1 (0.55) | XDHS1PR1CYP2D6 | |
| SCHEMBL14552812 | 0.72 | S1PR1 (0.63) | S1PR1CYP2D6 | |
| SCHEMBL3951343 | 0.70 | AAK1 (0.34) | S1PR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547662-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| WO-2011113309-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012491-A1 | PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | XDH 2603/4885S1PR1 1/4885RORC 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.